203 related articles for article (PubMed ID: 37432950)
1. Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways.
Ma W; Wu Z; Maghsoudloo M; Ijaz I; Dehghan Shasaltaneh M; Zhang Y; Weng Q; Fu J; Imani S; Wen QL
PLoS One; 2023; 18(7):e0285806. PubMed ID: 37432950
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Dermokine-α enhances the proliferation and epithelial-mesenchymal transition of pancreatic tumor cells.
Zhang Y; Zhang HW; Zhu XD; Wang YQ; Wang XW; Zheng BS; Chen BC; Chen ZJ
Cell Signal; 2022 Nov; 99():110439. PubMed ID: 35981655
[TBL] [Abstract][Full Text] [Related]
3. Comparative mRNA/micro-RNA co-expression network drives melanomagenesis by promoting epithelial-mesenchymal transition and vasculogenic mimicry signaling.
He W; Yang G; Liu S; Maghsoudloo M; Shasaltaneh MD; Kaboli PJ; Zhang C; Zhang J; Entezari M; Imani S; Wen Q
Transl Oncol; 2021 Dec; 14(12):101237. PubMed ID: 34626953
[TBL] [Abstract][Full Text] [Related]
4. Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic cancer.
Huang C; Xiang Y; Chen S; Yu H; Wen Z; Ye T; Sun H; Kong H; Li D; Yu D; Chen B; Zhou M
Cancer Sci; 2017 Nov; 108(11):2130-2141. PubMed ID: 28795470
[TBL] [Abstract][Full Text] [Related]
5. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
Fenouille N; Tichet M; Dufies M; Pottier A; Mogha A; Soo JK; Rocchi S; Mallavialle A; Galibert MD; Khammari A; Lacour JP; Ballotti R; Deckert M; Tartare-Deckert S
PLoS One; 2012; 7(7):e40378. PubMed ID: 22911700
[TBL] [Abstract][Full Text] [Related]
6. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
Li L; Zhang S; Li H; Chou H
BMC Cancer; 2019 Oct; 19(1):963. PubMed ID: 31619201
[TBL] [Abstract][Full Text] [Related]
7. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways.
Pal HC; Sharma S; Strickland LR; Katiyar SK; Ballestas ME; Athar M; Elmets CA; Afaq F
PLoS One; 2014; 9(1):e86338. PubMed ID: 24466036
[TBL] [Abstract][Full Text] [Related]
8. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
Perotti V; Baldassari P; Molla A; Nicolini G; Bersani I; Grazia G; Benigni F; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2019 May; 38(22):4384-4396. PubMed ID: 30710146
[TBL] [Abstract][Full Text] [Related]
9. ETS1 promoted cell growth, metastasis and epithelial-mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression.
Yang LX; Guo HB; Liu SY; Feng HP; Shi J
Melanoma Res; 2021 Aug; 31(4):298-308. PubMed ID: 34039939
[TBL] [Abstract][Full Text] [Related]
10. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.
Cheng PF; Shakhova O; Widmer DS; Eichhoff OM; Zingg D; Frommel SC; Belloni B; Raaijmakers MI; Goldinger SM; Santoro R; Hemmi S; Sommer L; Dummer R; Levesque MP
Genome Biol; 2015 Feb; 16(1):42. PubMed ID: 25885555
[TBL] [Abstract][Full Text] [Related]
11. Overexpressed VEPH1 inhibits epithelial-mesenchymal transition, invasion, and migration of human cutaneous melanoma cells through inactivating the TGF-β signaling pathway.
Feng H; Jia XM; Gao NN; Tang H; Huang W; Ning N
Cell Cycle; 2019 Nov; 18(21):2860-2875. PubMed ID: 31599708
[TBL] [Abstract][Full Text] [Related]
12. WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial-mesenchymal transition.
Deng W; Fernandez A; McLaughlin SL; Klinke DJ
J Biol Chem; 2019 Apr; 294(14):5261-5280. PubMed ID: 30723155
[TBL] [Abstract][Full Text] [Related]
13. Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/ NRAS mutated metastatic melanoma cells.
Thatikonda S; Pooladanda V; Tokala R; Nagula S; Godugu C
Toxicol In Vitro; 2023 Jun; 89():105579. PubMed ID: 36870549
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
Pearlman RL; Montes de Oca MK; Pal HC; Afaq F
Cancer Lett; 2017 Apr; 391():125-140. PubMed ID: 28131904
[TBL] [Abstract][Full Text] [Related]
15. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?
Mitchell B; Leone DA; Feller JK; Yang S; Mahalingam M
Hum Pathol; 2016 Jun; 52():19-27. PubMed ID: 26980024
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of aristaless-like homeobox1 inhibits epithelial-mesenchymal transition through Wnt/β-catenin signaling pathway in melanoma cells.
Jiao JX; Jiao LJ; Yang S; Zhao YJ
Biochem Biophys Res Commun; 2019 Mar; 511(1):105-110. PubMed ID: 30773258
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal-like transition events in melanoma.
Pedri D; Karras P; Landeloos E; Marine JC; Rambow F
FEBS J; 2022 Mar; 289(5):1352-1368. PubMed ID: 33999497
[TBL] [Abstract][Full Text] [Related]
18. PI3K signalling is required for a TGFβ-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells.
Schlegel NC; von Planta A; Widmer DS; Dummer R; Christofori G
Exp Dermatol; 2015 Jan; 24(1):22-8. PubMed ID: 25363503
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Bmi-1 suppresses epithelial‑mesenchymal transition in melanoma.
Liu Y; Chu Z; Li Q; Peng B; Xu S; Lian CG; Geng S
Oncol Rep; 2017 Jan; 37(1):139-146. PubMed ID: 27878257
[TBL] [Abstract][Full Text] [Related]
20. Mice deficient for the epidermal dermokine β and γ isoforms display transient cornification defects.
Leclerc EA; Huchenq A; Kezic S; Serre G; Jonca N
J Cell Sci; 2014 Jul; 127(Pt 13):2862-72. PubMed ID: 24794495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
